Fludarabine Phosphate Injection Recalled Due to Sterility Concern
Custopharm, Inc. is recalling Fludarabine Phosphate for Injection, USP 50 mg because the manufacturer detected microbial contamination during environmental monitoring in aseptic manufacturing areas, raising sterility assurance concerns.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This recall is FDA Class II for a sterility defect in an injectable drug. Although no illnesses or injuries are reported in the source text, a compromised sterility assurance in an intravenous chemotherapy agent (fludarabine is used to treat hematologic malignancies) poses significant risk of serious infection. Class II classification with a high-risk injectable product warrants a Severe rating.
Plain-English summary
Custopharm, Inc. is recalling Fludarabine Phosphate for Injection, USP 50 mg per vial (NDC 24201-237-01, Lot# 31327913C, Expiration Date 10/2022) due to a lack of assurance of sterility.
The recall was initiated because the manufacturing firm detected microbial recoveries during environmental monitoring in aseptic areas of the manufacturing facility. This finding indicates a potential breach in the sterility assurance process for the affected lot.
The recalled product was distributed nationwide in the USA. Patients receiving this product should contact their healthcare provider or pharmacist for guidance regarding their treatment. Healthcare providers should verify whether they dispensed this specific lot and should not administer any units from Lot# 31327913C.
The recalled product
- Product
- FLUDARABINE PHOSPHATE FOR INJECTION, USP, 50 mg per vial, Single dose vial, Rx Only, Mfd for: Leucadia Pharmaceuticals Carlsbad, CA 92011 U.S.A, NDC 24201-237-01
- Manufacturer
- Custopharm, Inc.
- Category
- Drug — Injectable / Oncology
- Hazard
- sterility-assurance
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 31327913C
- Exp. Date 10/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27